Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
PR Newswire (Apr 25, 2013)
-
-
-
-
-
-
PR Newswire (Mar 25, 2013)
-
-
-
-
-
PR Newswire (Feb 26, 2013)
To learn more about Seeking Alpha Pro, click here.
-
-
United Therapeutics: Estimates On An UpswingZacks Investment Research • Mon, Oct 15, 2012 -
-
4 Reasons To Buy United TherapeuticsMarkus Aarnio • Tue, Jun 5, 2012
-
-
-
-
-
United Therapeutics Swings to Profit in Q4Proactive Investor • Wed, Feb 16, 2011 -
-
United Therapeutics Corporation Special CallWed, Aug 24, 2011
-
United Therapeutics Corporation Q4 2009 Earnings Call TranscriptTue, Feb 16, 2010
-
United Therapeutics Corp. Q2 2009 Earnings Call TranscriptFri, Jul 31, 2009
-
United Therapeutics Corporation Q4 2008 Earnings Call TranscriptTue, Feb 17, 2009
-
United Therapeutics Corporation Q2 2008 Earnings Call TranscriptThu, Jul 31, 2008
-
United Therapeutics Corp. Q1 2008 Earnings Call TranscriptFri, May 2, 2008
-
United Therapeutics Corp. Q4 2007 Earnings Call TranscriptTue, Feb 19, 2008
-
at MarketWatch.com (Apr 30, 2013)
-
PR Newswire (Apr 25, 2013)
-
PR Newswire (Mar 25, 2013)
-
PR Newswire (Feb 26, 2013)
-
PR Newswire (Feb 14, 2013)
-
PR Newswire (Feb 4, 2013)
-
PR Newswire (Nov 1, 2012)
-
at MarketWatch.com (Oct 24, 2012)
-
PR Newswire (Oct 23, 2012)
-
at CNBC.com (Oct 10, 2012)
-
at MarketWatch.com (Sep 25, 2012)
-
at Fox Business (Aug 15, 2012)
-
PR Newswire (Jul 26, 2012)
-
PR Newswire (Jun 27, 2012)
-
PR Newswire (Apr 26, 2012)
UTHR vs. ETF Alternatives
Company Description
We are a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Our key therapeutic platforms are:
Prostacyclin Analogues, which are stable synthetic... More
